This Week in Addiction Medicine from ASAM Podcast Por American Society of Addiction Medicine arte de portada

This Week in Addiction Medicine from ASAM

This Week in Addiction Medicine from ASAM

De: American Society of Addiction Medicine
Escúchala gratis

This Week in Addiction Medicine is an audio summary of the recent top stories and research articles from the field of addiction medicine. Intended to serve as an accompaniment to the ASAM Weekly newsletter or as a stand-alone resource, This Week covers recent publications in addiction medicine research.

Copyright 2022. All rights reserved.
Enfermedades Físicas Higiene y Vida Saludable Política y Gobierno Psicología Psicología y Salud Mental
Episodios
  • Lead: Cost-effectiveness of contingency management for methamphetamine use disorder: A model-based analysis
    Mar 24 2026

    Cost-effectiveness of contingency management for methamphetamine use disorder: A model-based analysis

    Addiction

    This study used a microsimulation model of methamphetamine use behavior among individuals with methamphetamine use disorder (MethUD) to assess the cost-effectiveness of contingency management (CM) for MethUD. Both 12-week and 24-week CM programs were modeled, using a maximum incentive of $750/patient, per SAMHSA guidelines. The model simulation was run for a cohort of 10,000 individuals with MethUD and looked at lifetime cost. Compared to no treatment, the model predicted an estimated net gain of 0.70 QALYs per person at a cost of $6850/QALY for a 12-week program, with an incremental cost-effectiveness ratio (ICER) of $9830/QALY. For a 24-week program, the benefit was 0.81 QALYs at a cost of $10,000, yielding an ICER of $12,312/QALY. This suggests that both durations of CM for MethUD are highly cost-effective, even at the maximum level of incentives.

    Read this issue of the ASAM Weekly

    Subscribe to the ASAM Weekly

    Visit ASAM

    Más Menos
    8 m
  • Lead: Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study
    Mar 17 2026

    Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study

    The BMJ

    This study investigated whether initiation of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with both reduced risks of incident alcohol, cannabis, cocaine, nicotine, opioid, and other substance use disorders (SUDs) in people with no history of SUDs (protocol 1) and with reduced risk of SUD-related adverse clinical outcomes among people with a pre-existing SUDs (protocol 2). Researchers found that use of GLP-1 receptor agonists was consistently associated with reduced risks of developing various incident SUDs, suggesting a broad preventive effect across multiple substance types. Use was also associated with reduced risks of adverse clinical outcomes in people with pre-existing SUDs. These observational data suggest a potential role for GLP-1 receptor agonists in both the prevention and treatment of various SUDs, warranting further evaluation.

    Read this issue of the ASAM Weekly

    Subscribe to the ASAM Weekly

    Visit ASAM

    Más Menos
    8 m
  • Lead: Does the total consumption model apply to cannabis use?
    Mar 12 2026

    Does the total consumption model apply to cannabis use?

    Addiction

    This repeated cross-sectional study based on annual surveys tested whether the total consumption model and its extension, the theory of collectivity, apply to adolescent cannabis use in Sweden. Frequency of cannabis use was measured by a question on how many occasions the respondent has used hashish or marijuana. The seven response alternatives ranged from 0 to 50 times or more. Increases in mean frequency use were associated with a higher prevalence of high-frequency users. Adolescent cannabis use in Sweden appears to conform to key predictions of the total consumption model and its extension, the theory of collectivity.

    Read this issue of the ASAM Weekly

    Subscribe to the ASAM Weekly

    Visit ASAM

    Más Menos
    7 m
Todavía no hay opiniones